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setting, there is a need for additional information on the clinical and economic 
impact of idelalisib to inform decisions about utilization, coverage, and reim-
bursement. OBJECTIVES: The objective of this study was to evaluate the cost-
effectiveness of idelalisib plus rituximab versus rituximab alone from a payer’s 
perspective. METHODS: We developed a partition survival model to evaluate ide-
lalisib plus rituximab versus rituximab alone. The model included three health 
states – Pre-Progressed, Progressed, and Death. The pivotal trial Study 116 (Furman 
et al., 2014) served as the basis for this study by providing data on Progression-
Free-Survival (PFS) and Overall-Survival (OS), dosing, and adverse events. We used 
longer-term data from a trial of bendamustine plus rituximab in CLL plus Weibull 
cumulative distribution functions to extrapolate incomplete PFS and OS curves. 
Cost data was derived from Wolters Kluwer Health, Centers for Medicare and 
Medicaid Services data, and publicly available literature. One-way and probabilistic 
sensitivity analyses were performed to evaluate uncertainty. We used a lifetime 
horizon, payer perspective, and a 3% discount rate. RESULTS: Total costs were 
$585,493 and QALYs were 3.34 for the idelalisib plus rituximab group, while total 
costs were $66,698 and QALYs were 1.20 for the rituximab alone group. This yielded 
an incremental cost-effectiveness ratio of $242,884/QALY. The result was most 
sensitive to changes in the hazard ratio for death and idelalisib drug costs. The 
probability that idelalisib was cost-effective was 1% at both a willingness to pay 
of $100,000/QALY and $150,000/QALY. CONCLUSIONS: Idelalisib plus rituximab 
does not appear to be cost-effective since it greatly exceeds the commonly cited 
thresholds of $100,000/QALY and $150,000/QALY. However, it is in line with other 
commonly used treatments in cancer.
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OBJECTIVES: Mortality associated with the lung cancer is maximum among all 
forms of cancer in the US. Among all lung cancer patients, 85% have non-small 
cell lung cancer (NSCLC). Of these NSCLC patients, 5% are EML4-ALK gene positive 
patients. In these patients, standard therapy [platinum doublet (cisplatin and gem-
citabine) as first-line therapy, pemetrexed as second-line therapy, and erlotinib as 
third-line therapy] has shown plateau effect. In 2014, FDA has approved Ceritinib as 
a first line therapy based on the results from phase one study, under the orphan drug 
category for ALK+NSLCC. Study aims to evaluate the cost-effectiveness of EML4-ALK 
fusion targeted ceritinib treatment as compare to treatment by standard therapy 
among ALK+NSCLC patients in the US. METHODS: A decision analytic model with 
the embedded Markov model was developed to compare the lifetime benefits in 
terms of quality adjusted life years [QALYs] and direct medical costs of the treatment 
strategies for patients with advanced NSCLC. Progression free survival rate during 
each treatment alternatives, rates of adverse events, mortality rates, and utility 
values on standard therapy and ceritinib were obtained from published literature. 
Cost inputs were based on 2013 Medicare reimbursement rates. Primary outcome of 
incremental cost effectiveness ratio (ICER) was estimated as an incremental cost of 
treating with Ceritinib per QALY gained. USD 100,000 was considered as the willing-
ness to pay threshold. RESULTS: The use of EML4-ALK targeted ceritinib treatment 
for EML4-ALK–positive advanced NSCLC results in added benefits (0.09 QALYs) and 
extra costs ($1897.82) for the average patient with NSCLC. The ICER was $21,263 for 
per QALY gained. CONCLUSIONS: Study suggests that the treatment by Ceritinib 
compared to the treatment by standard therapy alone is a cost-effective strategy 
based upon the decision analysis model. Study limitation includes non-inclusion 
of the cost of EML4-ALK gene testing, which could change the total treatment cost 
significantly.
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OBJECTIVES: Sorafenib is the first product approved for treatment of RAI refractory 
locally advanced/metastatic DTC patients. This study was conducted in order to 
analyze cost-effectiveness of sorafenib for treatment of patients with RAI refrac-
tory locally advanced/metastatic DTC in Turkey. METHODS: A cohort partition 
model assigning patients to one of three health states according to the proportion 
of patients who are progression-free, progressed, or dead in each 28-days cycle 
was adapted to Turkish setting. The incremental cost-effectiveness ratios (ICER) 
were calculated per quality-adjusted life years (QALYs) and life-years (LYs) gained. 
Turkish payer’s perspective was taken and time-horizon was set as patient’s lifetime 
(maximum 30 years). Sorafenib was compared to the best supportive care (BSC) 
within the model since there are no agents for treatment of patients on this stage 
of the disease. Essential clinical inputs were derived from DECISION trial and local 
resource-utilization data were based on expert opinions through an expert panel. 
Sensitivity of the results was evaluated in terms of key inputs by deterministic one-
way and probabilistic sensitivity analyses. All costs were calculated in Turkish Liras 
(TL) and converted to USD using TL/USD currency rate as 2.2 (mid-2014). RESULTS: 
Total cost of sorafenib-treated patients is 24,384 USD higher compared to BSC. 
Besides, sorafenib is associated with increments of 1.29 LYs and 0.80 QALYs com-
pared to BSC. The ICER of sorafenib per LYs and QALYs gained compared to BSC 
were determined as 18,851 USD and 30,485 USD respectively. One-way sensitivity 
analysis demonstrated that results are not sensitive to the changes in model inputs 
were performed on key variables and different vaccination scenarios. RESULTS: 
With 20% screen coverage and 20% vaccine coverage, quadrivalent vaccine plus 
screening by protocol 2 had the most attractive cost-effectiveness ratio ($6,691 per 
QALY saved) compared to when using a willingness to pay (WTP) for a QALY thresh-
old of $22,433 (three times of GDP per capita in China). The bivalent vaccine and 
its combination with the screening program could reduce much more incidence 
and mortality of cervical cancer compared to the quadrivalent vaccine, while the 
cost per QALY acquired of the quadrivalent vaccine is lower. The combined strate-
gies are cost-effective compared to the counterparts of vaccination alone and can 
achieve much more health benefits compared to screening alone. The coverage of 
the screening and the vaccination serve as a crucial factor of variations in the cost-
effectiveness of different strategies. CONCLUSIONS: HPV vaccinations integrated 
into the current screening programs are cost-effectiveness strategies, and should be 
considered a potential strategy to reduce disease burden of cervical cancer in China. 
Selection of the appropriate strategy can be flexible for policy makers, because of 
geographical and socioeconomic diversities.
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Abiraterone acetate (Abi) therapy showed survival and clinical benefits in the treat-
ment of metastatic castration-resistant prostate cancer (mCRPC) in phase III trials. In 
Quebec, Abi reimbursement was approved for docetaxel-naïve and refractory patients 
in 2014 and 2012, respectively.OBJECTIVES: Evaluated the cost-effectiveness and sur-
vival impact of Abi treatment in the management of CRPC post-docetaxel. METHODS: 
The study cohort was selected from the public healthcare insurance programs: Régie 
de l’Assurance Maladie du Québec (RAMQ) and Med-Echo databases. It consisted 
of patients with CRPC starting chemotherapy or abiraterone treatments beteween 
2009-2010 (docetaxel), defined as pre-Abi era, and 2012-2013 (docetaxel+Abi), defined 
as Abi era. Survival was evaluated by Kaplan-Maier and the difference in survival 
between pre-Abi and Abi eras by log-rank test. Association between Abi exposure 
and survival was evaluated by cox proportional hazards model adjusted for co-vari-
ables. The incremental cost-effectiveness ratio was obtained by dividing changes in 
costs (Docetaxel alone, Docetaxel+Abi) and survival in the two periods. RESULTS: 
Survival was significantly increased by the addition of Abi to CRPC management. 
Mean survival were 11.47 (±0.6; N= 115) vs 15.26 (± 0.85; N= 67) months in the pre-Abi 
vs Abi era (p< 0.001). Mean treatment duration for Abi was 163 days (±108.7) and for 
chemotherapy during Abi period was 4.4 cycles (±3.1) and 4.6 clycles in the pre-Abi 
era (±4.2). The adjusted harzard ratio when comparing pre-Abi vs Abi era was 1.32 
(95%CI 0.98-1.78). The cost per patient for docetaxel treatment was $3,680 and for 
docetaxel+Abi was C$49,650. As expected, the addition of Abi resulted in a cost incre-
ment of C$45,970/patient. The incremental cost-effectiveness ratio was C$145,569 per 
life-year gained. CONCLUSIONS: Our real-life study indicates that patients receiving 
Abi plus docetaxel had a survival benefit when compared to chemotherapy alone. 
Addition of Abi was associated with an important increase in CRPC therapy costs.
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OBJECTIVES: The objective of this study was to estimate Incremental Cost-
Effectiveness Ratio (ICER) of utilizing eribulin for Metastatic Breast Cancer 
(MBC) in Spain for the second line (2L) treatment of HER2 negative (HER2NEG) 
patients. METHODS: Eribulin is indicated for the treatment of patients with locally 
advanced or MBC who have progressed following one prior chemotherapeutic regi-
men (FOPC). An economic model was developed to evaluate the cost-effectiveness 
of eribulin in HER2NEG MBC FOPC population in Spain. The data on progression 
free survival and overall survival was derived from randomized clinical trial of 
eribulin against capecitabine (study 301). A five year partitioned survival model was 
developed to estimate the ICER of the patients in this sub-group. Health state utility 
data was obtained by mapping quality of life collected in study 301 to EQ-5D using 
validated algorithm. Frequencies of adverse events and utilization of direct medical 
resources were also obtained from study 301. Local Spain tariffs were applied for all 
costs i.e. drug, administration, adverse event treatment, and direct medical costs 
including hospitalization, physician visits, end of life and palliative care. RESULTS: 
Incremental life years (LYs) and Quality Adjusted Life Years (QALYs) gained by these 
patients were 0.26 and 0.23 respectively. At a cost of eribulin of € 320 per vial, the 
ICERs per LY and QALY saved were € 32,865 and € 36,951 respectively. Sensitivity 
analysis results were also consistent with the basecase findings. CONCLUSIONS: 
According to reviewed HTA decisions in the past, eribulin was found to be cost-
effective in 2L HER2NEG populations. Given the limited number of effective thera-
peutic options available to these patients, cost effective eribulin represents a valid 
option for optimizing the treatment pathways.
PCN79
idElAlisib Plus rituximAb vErsus PlACEbo Plus rituximAb for 
rElAPsEd ChroNiC lymPhoCytiC lEukEmiA: A Cost-EffECtivENEss 
ANAlysis
Yu J.S.1, Seal B.2, Carlson J.J.1
1University of Washington, Seattle, WA, USA, 2Bayer HealthCare Pharmaceuticals, Whippany, NJ, 
USA
BACKGROUND: No published economic evidence currently exists with regards 
to idelalisib for relapsed chronic lymphocytic leukemia (CLL). Given its recent 
approval, comparator products on the market, and the high cost of care in this 
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OBJECTIVES: Everolimus and sunitinib are indicated to treat patients with 
advanced, progressive pancreatic neuroendocrine tumors (pNETs). This analysis 
examines the projected cost-effectiveness of everolimus versus sunitinib in this 
setting from a Swedish payer’s perspective. METHODS: A lifetime Markov model 
was developed to simulate a cohort of advanced, progressive pNET patients to 
estimate the incremental cost-effectiveness when treating with everolimus (10 
mg/day) versus sunitinib (37.5 mg/day). Efficacy inputs were based on a weight-
adjusted indirect comparison of the therapies using the respective phase 3 trial 
data (Signorovitch et al. 2013 and data on file). The disease pathway is reflected 
through mutually exclusive health states: stable disease without adverse events, 
stable disease with adverse events, disease progression, and death. Unit costs 
were obtained from public official Swedish sources. The model includes only 
direct costs. Resource use was based on a German physician survey, validated 
and adapted to Swedish conditions. Costs were represented in 2014 Swedish Krona 
(SEK). The incremental cost-effectiveness ratio (ICER) was calculated. Two-way 
sensitivity analyses were conducted to test the model’s robustness. RESULTS: 
In the base case, the estimated gain of everolimus over sunitinib was 0.357 LYs 
(0.261 QALYs), which results in an ICER that ranges from 100,000 -200,000 SEK/
QALY depending on the assumptions around the duration of therapy for active 
treatment. The analysis is sensitive to the uncertainty of the indirect analysis 
results and variables such as dose intensity. CONCLUSIONS: This model, based 
on an indirect comparison of phase 3 studies, indicates that everolimus is cost-
effective relative to sunitinib in advanced pNET. Its reliance on an indirect analysis 
due to the lack of head-to-head randomized controlled trial data warrants future 
research; however, model results indicate that everolimus is a valuable treatment 
option for pNET patients in Sweden.
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OBJECTIVES: The aim of the study was to analyze the cost-effectiveness of 
cetuximab compared to bevacizumab, both in combination with cytotoxic 
chemotherapy (folinic acid, fluorouracil and irinotecan, FOLFIRI), for first-line 
treatment of RAS wild-type metastatic colorectal cancer, under the public per-
spective in Brazil. METHODS: A cost-effectiveness analysis has been developed 
based on a Markov model, comparing the use of cetuximab+FOLFIRI versus 
bevacizumab+FOLFIRI. Only 2014 direct medical costs were considered in the 
analyses and outcomes were measured in terms of life years saved. Efficacy 
data were obtained from the recently published clinical trial FIRE-3, a head-
to-head trial between cetuximab+FOLFIRI and Bevacizumab+FOLFIRI, and 
costs were obtained from national databases, reflecting the perspective of the 
public healthcare sector in Brazil as a third party payer. Costs and outcomes 
were discounted to present value at a 5% annual rate. The time horizon con-
sidered 10 years. The total number of patients was calculated by the number 
of patients currently receiving chemotherapy who would be considered RAS 
wild-type and eligible to use cetuximab. RESULTS: In a 10 years time horizon, 
the use of cetuximab + FOLFIRI achieved clinical gains of 0,51 life years saved 
compared to bevacizumab + FOLFIRI, with an average cost reduction of R$1,953 
per patient. Cetuximab was shown to be a dominant therapy compared to bev-
acizumab, saving resources up to BRL 14,450,940.00 considering 5,171 patients 
in 2015. CONCLUSIONS: The use of cetuximab as first-line treatment for wild-
type RAS metastatic colorectal cancer has shown significant and clinically 
meaningful benefits while being cost-saving to the Brazilian public healthcare 
system.
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OBJECTIVES: Population-wide screening for epidermal growth factor receptor (EGFR) 
mutations and anaplastic lymphoma kinase (ALK) gene rearrangements to inform 
cancer therapy in non-small cell lung cancer (NSCLC) is recommended by guidelines. 
We estimated cost-effectiveness of multiplexed predictive biomarker screening in 
metastatic NSCLC from a societal perspective in the US. METHODS: We constructed 
a microsimulation model to compare the life expectancy and costs of multiplexed 
testing and molecularly guided therapy vs treatment with cisplatin-pemetrexed 
(CisPem). All testing interventions included a two-step algorithm of concurrent 
EGFR mutation and ALK overexpression testing with immunohistochemistry (IHC) 
followed by ALK rearrangement confirmation with a fluorescence in situ hybridiza-
tion (FISH) assay for IHC positive results. Three strategies were included: ‘Test-treat’ 
approach, where molecularly guided therapy was initiated after obtainment of test 
results; ‘Empiric switch therapy’, with concurrent initiation of CisPem and testing 
and immediate switch to test-result conditional treatment after one cycle of CisPem; 
and ‘Empiric therapy’ approach in which CisPem was continued for four cycles before 
start of a tyrosine kinase inhibitor (TKI). RESULTS: The incremental cost-effective-
ness ratio (ICER) for ‘Test-treat’ compared to treatment with CisPem was $136,000 
per quality-adjusted life year (QALY) gained. Both empiric treatment approaches 
had less favorable ICERs. ‘Test-treat’ and ‘Empiric switch therapy’ yielded higher 
expected outcomes in terms of QALYs and life-years (LYs) than ‘Empiric therapy’. 
These results were robust across plausible ranges of model inputs. CONCLUSIONS: 
From a societal perspective, our cost-effectiveness results support the value 
of multiplexed genetic screening and molecularly guided therapy in metastatic 
NSCLC.
and pharmacoeconomic analysis results were validated by probabilistic sensitiv-
ity analysis. CONCLUSIONS: Sorafenib is cost-effective for treatment of patients 
with RAI refractory locally advanced/metastatic DTC compared to BSC with an 
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OBJECTIVES: To evaluate the cost-effectiveness of primary prophylaxis (PP) with 
pegfilgrastim vs lipegfilgrastim to reduce the incidence of febrile neutropenia (FN) 
in patients with stage II breast cancer receiving 4-cycle TC (docetaxel, cyclophos-
phamide) and patients with non-Hodgkin lymphoma receiving 6-cycle R-CHOP 
(rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) over a life-
time horizon from a Belgian payer perspective. METHODS: A Markov cycle tree 
model tracks FN events during chemotherapy (3-week cycles) and long-term sur-
vival (1-year cycles). Model inputs include: the odds ratio of FN between lipegfil-
grastim PP and pegfilgrastim PP (median [95% credible interval]: 1.39 [0.54–3.50]), 
estimated from a meta-analysis of randomized controlled trials using mixed-
treatment comparison; equivalent prices of lipegfilgrastim and pegfilgrastim since 
the launch of lipegfilgrastim in Belgium (August 2014); mortality (which is affected 
by FN and chemotherapy relative dose intensity); costs (in 2014 € ); and utilities. 
All inputs were estimated from public sources, research databases, and peer-
reviewed publications. Quality-adjusted life-years (QALYs) and expected lifetime 
costs were estimated for each strategy. Probabilistic sensitivity analyses (PSA) 
and scenario analyses were conducted. RESULTS: Pegfilgrastim PP dominated 
lipegfilgrastim PP, with total lifetime costs of € 7,482 vs € 7,806 for TC and € 19,149 
vs € 19,801 for R-CHOP and total lifetime QALYs of 13.379 vs 13.348 for TC and 
4.241 vs 4.184 for R-CHOP. At a willingness-to-pay threshold of € 30,000 per QALY, 
pegfilgrastim PP was cost-effective vs lipegfilgrastim PP in approximately 75% of 
PSA simulations for both regimens. In a scenario analysis when the lipegfilgrastim 
price was set at 90% that of pegfilgrastim, the incremental cost-effectiveness 
ratios for pegfilgrastim PP vs lipegfilgrastim PP were € 4,700 per QALY gained for 
TC and € 857 per QALY gained for R-CHOP. CONCLUSIONS: From a Belgian payer 
perspective, pegfilgrastim PP is cost-effective vs lipegfilgrastim PP in patients with 
stage II breast cancer receiving TC and in patients with non-Hodgkin lymphoma 
receiving R-CHOP.
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